Fibroblast growth factor receptor 1 promotes MG63 cell proliferation and is associated with increased expression of cyclin-dependent kinase 1 in osteosarcoma

Zhou,Wei; Zhu,Yue; Chen,Song; Xu,Ruijun; Wang,Kunzheng

doi:10.3892/mmr.2015.4597

Fibroblast growth factor receptor 1 promotes MG63 cell proliferation and is associated with increased expression of cyclin-dependent kinase 1 in osteosarcoma

Authors:
- Wei Zhou
- Yue Zhu
- Song Chen
- Ruijun Xu
- Kunzheng Wang
View Affiliations

Affiliations: Department of Orthopaedics, The Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai 200233, P.R. China, Department of Orthopaedics, The Second Hospital Affiliated to Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China
Published online on: November 23, 2015 https://doi.org/10.3892/mmr.2015.4597
Pages: 713-719
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most common type of malignant bone tumor in adolescents and young adults. However, current understanding of osteosarcomagenesis remains limited. In the present study, the role of fibroblast growth factor receptor 1 (FGFR1) in human osteosarcoma cell proliferation was investigated, and the possible pathways that contribute to FGFR1‑mediated osteosarcoma cell proliferation were examined using microarray analysis. The expression of FGFR1 in osteosarcoma tissues was assessed by reverse transcription-quantitative polymerase chain reaction and immunohistochemistry. The results demonstrated that FGFR1 was markedly increased in osteosarcoma tissues, and that the overexpression of FGFR1 in MG63 cells significantly promoted cell proliferation, as observed using the cell viability assay. In addition, FGFR1‑mediated cell proliferation was closely associated with cell cycle re‑distribution, as determined by microarray analysis. Western blotting identified that the expression of cyclin-dependent kinase 1 (CDK1) was correspondingly increased in response to the overexpression of FGFR1. These results indicated that FGFR1 contributes to cell proliferation in osteosarcoma MG63 cells, and FGFR1 mediated cell proliferation may be attributed to the regulation of the cell cycle regulator, CDK1. These findings provide evidence to support the potential use of molecule target therapy against FGFR1 as a promising strategy in osteosarcoma treatment and prevention.

View Figures

View References

1	Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
2	Kang K, Lee JH and Kim HG: Contralateral referred pain in a patient with intramedullary spinal cord metastasis from extraskeletal small cell osteosarcoma. J Spinal Cord Med. 36:695–699. 2013. View Article : Google Scholar : PubMed/NCBI
3	Chou AJ, Geller DS and Gorlick R: Therapy for osteosarcoma: Where do we go from here? Paediatr Drugs. 10:315–327. 2008. View Article : Google Scholar : PubMed/NCBI
4	Ahmad I, Iwata T and Leung HY: Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta. 1823.850–860. 2012.
5	Liang G, Liu Z, Wu J, Cai Y and Li X: Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci. 33:531–541. 2012. View Article : Google Scholar : PubMed/NCBI
6	Wesche J, Haglund K and Haugsten EM: Fibroblast growth factors and their receptors in cancer. Biochem J. 437:199–213. 2011. View Article : Google Scholar : PubMed/NCBI
7	Johnson DE and Williams LT: Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 60:1–41. 1993. View Article : Google Scholar : PubMed/NCBI
8	Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et al: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 10:529–541. 2006. View Article : Google Scholar : PubMed/NCBI
9	Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rougé C, Lasorsa L, Letessier A, Ginestier C, Monville F, et al: Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res. 3:655–667. 2005. View Article : Google Scholar : PubMed/NCBI
10	Jacquemier J, Adelaide J, Parc P, Penault-Llorca F, Planche J, deLapeyriere O and Birnbaum D: Expression of the FGFR1 gene in human breast-carcinoma cells. Int J Cancer. 59:373–378. 1994. View Article : Google Scholar : PubMed/NCBI
11	McDonald ER III and El-Deiry WS: Cell cycle control as a basis for cancer drug development (Review). Int J Oncol. 16:871–886. 2000.PubMed/NCBI
12	Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NC and Van Etten RA: Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 trans-locations. Cancer Cell. 5:287–298. 2004. View Article : Google Scholar : PubMed/NCBI
13	Xiao S, Nalabolu SR, Aster JC, Ma J, Abruzzo L, Jaffe ES, Stone R, Weissman SM, Hudson TJ and Fletcher JA: FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet. 18:84–87. 1998. View Article : Google Scholar : PubMed/NCBI
14	Yagasaki F, Wakao D, Yokoyama Y, Uchida Y, Murohashi I, Kayano H, Taniwaki M, Matsuda A and Bessho M: Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12) (p16;p13) chromosomal translocation. Cancer Res. 61:8371–8374. 2001.PubMed/NCBI
15	Clark JC, Tichelaar JW, Wert SE, Itoh N, Perl AK, Stahlman MT and Whitsett J: FGF-10 disrupts lung morphogenesis and causes pulmonary adenomas in vivo. Am J Physiol Lung Cell Mol Physiol. 280:L705–L715. 2001.PubMed/NCBI
16	Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, et al: Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol. 75:196–207. 2009. View Article : Google Scholar :
17	van Rhijn BW, van Tilborg AA, Lurkin I, Bonaventure J, de Vries A, Thiery JP, van der Kwast TH, Zwarthoff EC and Radvanyi F: Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet. 10:819–824. 2002. View Article : Google Scholar : PubMed/NCBI
18	Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, et al: Patterns of somatic mutation in human cancer genomes. Nature. 446:153–158. 2007. View Article : Google Scholar : PubMed/NCBI
19	Naski MC, Wang Q, Xu J and Ornitz DM: Graded activation of fibroblast growth factor receptor 3 by mutations causing achon-droplasia and thanatophoric dysplasia. Nat Genet. 13:233–237. 1996. View Article : Google Scholar : PubMed/NCBI
20	Gru AA and Allred DC: FGFR1 amplification and the progression of non-invasive to invasive breast cancer. Breast Cancer Res. 14:1162012. View Article : Google Scholar : PubMed/NCBI
21	Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Fraser Symmans W, Hortobagyi GN, Andre F and Pusztai L: Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat. 123:747–755. 2010. View Article : Google Scholar
22	Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, et al: Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 6:e203512011. View Article : Google Scholar : PubMed/NCBI
23	Tran TN, Selinger CI, Kohonen-Corish MR, McCaughan BC, Kennedy CW, O'Toole SA and Cooper WA: Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer. 81:462–467. 2013. View Article : Google Scholar : PubMed/NCBI
24	Ren M, Hong M, Liu G, Wang H, Patel V, Biddinger P, Silva J, Cowell J and Hao Z: Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncol Rep. 29:2181–2190. 2013.PubMed/NCBI
25	Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, Ayala GE, Peterson LE, Ittmann M and Spencer DM: Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial- to -mesenchymal transition. Cancer Cell. 12:559–571. 2007. View Article : Google Scholar : PubMed/NCBI
26	Lehnen NC, von Mässenhausen A, Kalthoff H, Zhou H, Glowka T, Schütte U, Höller T, Riesner K, Boehm D, Merkelbach-Bruse S, et al: Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology. 63:157–166. 2013. View Article : Google Scholar : PubMed/NCBI
27	Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Mühling J, Hofele C, Radlwimmer B, Lichter P and Joos S: Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 43:60–66. 2007. View Article : Google Scholar
28	Simon R, Richter J, Wagner U, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knönagel H, et al: High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 61:4514–4519. 2001.PubMed/NCBI
29	Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, Choong DY and Campbell IG: High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res. 13:4731–4739. 2007. View Article : Google Scholar : PubMed/NCBI
30	Missiaglia E, Selfe J, Hamdi M, Williamson D, Schaaf G, Fang C, Koster J, Summersgill B, Messahel B, Versteeg R, et al: Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer. 48:455–467. 2009. View Article : Google Scholar : PubMed/NCBI
31	Guimarães JM, Guimarães IC, Duarte ME, Vieira T, Vianna VF, Fernandes MB, Vieira AR and Casado PL: Polymorphisms in BMP4 and FGFR1 genes are associated with fracture non-union. J Orthop Res. 31:1971–1979. 2013. View Article : Google Scholar : PubMed/NCBI
32	Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, LaQuaglia MP, Huvos AG and Meyers PA: Treatment of osteosarcoma at first recurrence after contemporary therapy: The memorial sloan-kettering cancer center experience. Cancer. 104:2214–2221. 2005. View Article : Google Scholar : PubMed/NCBI
33	He H, Ni J and Huang J: Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett. 7:1352–1362. 2014.PubMed/NCBI
34	Mougeot JL, Li Z, Price AE, Wright FA and Brooks BR: Microarray analysis of peripheral blood lymphocytes form ALS patients and the SAFE detection of the KEGG ALS pathway. BMC Med Genomics. 25:74–80. 2011. View Article : Google Scholar
35	Morgan DO: Principles of CDK regulation. Nature. 374:131–134. 1995. View Article : Google Scholar : PubMed/NCBI
36	Benson C, Kaye S, Workman P, Garrett M, Walton M and de Bono J: Clinical anticancer drug development: Targeting the cyclin-dependent kinases. Br J Cancer. 92:7–12. 2005. View Article : Google Scholar
37	Liu L, Xu Y and Reiter RJ: Melatonin inhibits the proliferation of human osteosarcoma cell line MG-63. Bone. 55:432–438. 2013. View Article : Google Scholar : PubMed/NCBI
38	Kang J, Sergio CM, Sutherland RL and Musgrove EA: Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer. 14:322014. View Article : Google Scholar : PubMed/NCBI